Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.

NCT02202135 ↗

Phase 3 Terminated 4 enrolled Pfizer Forest Laboratories · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.

Timeline

Start: 2014-06
Primary completion: 2015-01
Completion: 2015-01

Publications

Dryden M, Zhang Y, Wilson D, Iaconis JP, Gonzalez J. A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities. J Antimicrob Chemother. 2016 Dec;71(12):3575-3584. doi: 10.1093/jac/dkw333. Epub 2016 Sep 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aztreonam	Small molecule	1 g	Intravenous
Subject	Ceftaroline fosamil	Other / unclassified	600 mg	Intravenous
Comparator	Vancomycin	Other / unclassified	15 mg/kg	Intravenous

Indications

No indication recorded.